<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-645-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEVAC  10 mg Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESCITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX INC. (SIGNET SITE)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a-</u></strong><u> <strong>What APO-ESCITALOPRAM is</strong></u></p><p>The name of your medicine is APO-ESCITALOPRAM. It contains the active ingredient, escitalopram oxalate.</p><p>APO-ESCITALOPRAM is used to treat depression. It belongs to a group of medicines called selective serotonin reuptake inhibitors (SSRis). They are thought to work by their actions on brain chemicals called amines, which are involved in controlling mood. Depression is longer lasting or more severe than the &quot;low moods&quot; everyone has from time to time due to the stress of everyday life. It is thought to be caused by chemical imbalance in parts of the brain. This imbalance affects your whole body and can cause emotional and physical symptoms such as feeling low in spirit, loss of interest in activities, being unable to enjoy life, poor appetite or overeating, disturbed sleep, often waking up early, loss of sex drive, lack of energy and feeling guilty over nothing.</p><p>&nbsp;</p><p><strong><u>b-</u></strong><u> <strong>What APO-ESCITALOPRAM is taken for</strong></u></p><p>APO-ESCITALOPRAM corrects this chemical imbalance and may help relieve the symptoms of depression. APO-ESCITALOPRAM may also be used to treat patients who many avoid and/or are fearful of social situations. APO-ESCITALOPRAM may also be used to treat patients who have excessive anxiety and worry. APO-ESCITALOPRAM may also be used to treat irrational fears or obsessional behaviour (obsessive-compulsive disorder}. Obsessive-compulsive disorder involves having both obsessions and compulsions. Obsessions are unwanted thoughts that occur over and over again. Compulsions are the ongoing need to repeat certain actions as a result of these thoughts. Your doctor, however, may prescribe APO-ESCITALOPRAM for another reason.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a- Do not take APO-ESCITALOPRAM</u></strong></p><ul><li>if you have had an allergic reaction to It, to any other medicine containing citalopram or any of the ingredients listed at the end of this leaflet.</li><li>if you are intolerant or allergic to lactose &ndash; APO-ESCITALOPRAM tablets contain lactose. Symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue or other parts of the body, or rash, itching or hives on the skin.</li><li>at the same time as the following other medicines:<ul><li>pimozide, a medicine used to treat mental disorders</li><li>monoamine oxidase inhibitors (MAIOs), which are also used for the treatment of depression</li></ul></li><li>when you are taking a MAOI or when you have been taking a MAOI within the last 14 days. Taking APO-ESCITALOPRAM with MAOIs may cause a serious reaction with a sudden increase in body temperature, extremely high blood pressure and severe convulsions.&nbsp; Your doctor will know when it is safe to start APO-ESCITALOPRAM after the MAOI has been stopped.</li><li>after the expiry date (EXP) printed on the pack.<strong> </strong>If you take this medicine after the expiry date has passed, it may not work as well.</li><li>Do not take APO-ESCITALOPRAM if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.</li><li>Do not give the tablets to anyone else, even if they have the same condition as you.</li><li>Do not take APO-ESCITALOPRAM to treat any other complaints unless your doctor tells you to.</li></ul><p>&nbsp;</p><p><strong><u>b- Take special care</u></strong></p><p><strong>Before you start to take it Tell your doctor if:</strong></p><ul><li>you have allergies to any other substances such as foods, preservatives or dyes.</li><li>you have, or have had, the following medical conditions: bleeding disorder, diabetes, heart disease, kidney disease, liver disease, bipolar disorder (manic depression), and a history of seizures or fits.</li><li>Do not give APO-ESCITALOPRAM to a child or adolescent. There is no experience with its use in children and adolescents under 18 years of age.</li><li>APO-ESCITALOPRAM can be given to elderly patients over 65 years of age with a reduced dose. The effects of APO-ESCITALOPRAM in elderly patients are similar to that in other patients.</li><li>If you have not told your doctor about any of the above, tell them before you start taking APO-ESCITALOPRAM.</li></ul><p>&nbsp;</p><p><strong><u>c- Pregnancy and breast-feeding</u></strong></p><p>Do not take APO-ESCITALOPRAM if you are pregnant unless you and your doctor have discussed the risks and benefits involved. The general condition of your newborn baby might be affected by medicines like APO-ESCITALOPRAM.</p><p>Do not take APO-ESCITALOPRAM if you are breast&shy; feeding unless you and your doctor have discussed the risks and benefits involved. It is not recommended that you breast&shy; feed while taking APO-ESCITALOPRAM as it is excreted in breast milk.</p><p>&nbsp;</p><p><strong><u>b- Driving and using machines</u></strong></p><p>Be careful while driving or operating machinery until you know how APO-ESCITALOPRAM affects you. It may cause nausea, fatigue and dizziness in some people, especially early in the treatment. If you have any of these symptoms, do not drive, operate machinery, or do anything else that could be dangerous.</p><p>&nbsp;</p><p><strong><u>e- Interactions with this medication</u></strong></p><p><strong>Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.</strong></p><p>Some medicines and APO-ESCITALOPRAM may interfere with each other. These include:</p><ul><li>buproprion, a medicine helping&nbsp; to treat nicotine dependence</li><li>medicines used to treat reflux and ulcers,such as cimetidine, omeprazole, esomeprazole and lansoprazole</li><li>medicines known to prolong bleeding, e.g. aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)</li><li>ticlopidine and warfarin, medicines used to prevent blood clots</li><li>mefloquine, an anti-malaria medicine</li><li>sumatriptan, used to treat migraines</li><li>tramadol, used to relieve pain</li><li>medicines&nbsp; affecting the chemicals in the brain</li><li>some heart medications, e.g. flecainide, propafenone, metoprolol</li><li>tryptophan, an amino-acid</li><li>lithium, used to treat mood swings and some types of depression</li><li>antipsychotics, a class of medicines used to treat certain mental and emotional conditions, e.g. risperidone, thioridazine and haloperidol</li><li>tricyclic antidepressant, e.g. imipramine,&nbsp; desipramine</li><li>StJohn&#39;s Wort <em>(Hypericum perforatum), </em>a herbal remedy</li><li>any other medicines for depression, anxiety, obsessive-compulsive disorder or pre- menstrual dysphoric disorder.</li></ul><p>&nbsp;</p><p>These medicines may be affected by APO-ESCITALOPRAM, or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines. Your doctor will advise you.</p><p>&nbsp;</p><p>Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking APO-ESCITALOPRAM.</p><p>&nbsp;</p><p>Avoid alcohol while you are taking this medicine. It is not advisable to drink alcohol while you are being treated for depression.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Follow all directions given to you by your doctor or pharmacist carefully.</strong></p><p>&nbsp;</p><p><strong><u>a- How much APO-ESCITALOPRAM to take</u></strong></p><p>Your doctor will decide what dose you will receive. The standard dose for this medicine is 10 mg per day. This may be increased by your doctor to 20 mg per day. The recommended maximum dose with elderly patients is 10 mg per day. It is recommended that patients with liver disease receive an initial dose of 5 mg daily for the first two weeks. Your doctor may increase the dose to 10 mg daily. Your doctor may have prescribed a different dose. Ask your doctor or pharmacist if you are unsure of the correct dose for you. They will tell you exactly how much to take. Follow the instructions they give you. If you take the wrong dose, APO-ESCITALOPRAM may not work as well and your condition may not improve.</p><p>&nbsp;</p><p><strong><u>b- How and When to take APO-ESCITALOPRAM</u></strong></p><p>Swallow the tablets whole with a full glass of water. Do not chew them. Take APO-ESCITALOPRAM as a single dose either in the morning or in the evening. Take APO-ESCITALOPRAM with or without food. Continue to take APO-ESCITALOPRAM even if it takes some time before you feel any improvement in your condition. As with other medicines for the treatment of these conditions, it may take a few weeks before you feel any improvement. Individuals will vary greatly in their response to APO-ESCITALOPRAM. Your doctor will check your progress at regular intervals. The duration of treatment may vary for each individual, but is usually at least 6 months. In some cases, the doctor may decide that longer treatment is necessary. Continue taking your medicine for as long as your doctor tells you, even if you begin to feel better. The underlying illness may persist for a long time and if you stop your treatment too soon, your symptoms may return. Do not stop taking this medicine suddenly. Your doctor will tell you how to reduce the dosage so that you do not get unwanted side effects.</p><p>&nbsp;</p><p><strong><u>c- If you take more APO-ESCITALOPRAM than should</u></strong></p><p>Immediately telephone your doctor, or the Poisons Information Centre, or go to the Accident and Emergency</p><p>Department at your nearest hospital, if you think that you or anyone else may have taken too much APO-ESCITALOPRAM. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.</p><p>Symptoms of an overdose may include dizziness, low blood pressure, nausea (feeling sick), vomiting, agitation, tremor (shaking) and rarely convulsions and coma</p><p>&nbsp;</p><p><strong><u>d- If you forget to take APO-ESCITALOPRAM</u></strong></p><p>If you missed a dose and remember in less than 12 hours, take it straight away, and then go back to taking it as you would normally. Otherwise, if it is almost time for your next dose, skip the dose you missed and take the next dose when you are meant to. Do not take a double dose to make up for the dose that you have missed.</p><p>If you are not sure what to do, ask your doctor or pharmacist.</p><p>If you have trouble remembering when to take your medicine, ask your pharmacist for some hints.</p><p>Do not stop taking APO-ESCITALOPRAM, or lower the dosage, without checking with your doctor.</p><p>Do not let yourself run out of medicine over the weekend or on holidays.</p><p>Suddenly stopping APO-ESCITALOPRAM may cause unwanted discontinuation symptoms, such as dizziness, headache and nausea. Your doctor will tell you when and how APO-ESCITALOPRAM should be discontinued. You doctor will gradually reduce the amount you are using, usually over a period of one to two weeks, before stopping completely.</p><p>&nbsp;</p><p><strong><u>e- While you are taking APO-ESCITALOPRAM</u></strong></p><p>If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking APO-ESCITALOPRAM. Tell any other doctors, dentists, and pharmacists who are treating you that you are taking this medicine.</p><p>If you become pregnant while taking APO-ESCITALOPRAM, tell your doctor immediately.</p><p>Tell your doctor immediately if you have any suicidal thoughts or other mental or mood changes. All mention of suicide or violence must be taken seriously.</p><p>If you or someone you know demonstrates any of the following warning signs of suicide-related behaviour while taking APO-ESCITALOPRAM, contact a health care provider immediately, or <strong>even to go to the nearest hospital for treatment:</strong></p><ul><li>thoughts or talk of death or suicide</li><li>thoughts of talk of self-harm or harm to others</li><li>any recent attempts of self&shy;harm</li><li>increase in aggressive behaviour, irritability or agitation.</li></ul><p>&nbsp;</p><p><strong>Contact your doctor as soon as possible if you suddenly experience an episode of mania.</strong></p><p>&nbsp;</p><p>Some patients with bipolar disorder (manic depression) may enter into a manic phase. This is characterised by profuse and rapidly changing ideas, exaggerated gaiety and excessive physical activity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>All medicines may have some unwanted side effects. Sometimes they are serious, but most of the time, they are not. Your doctor has weighed the risks of using this medicine against the benefits he/she expects it will have for you.</p><p>APO-ESCITALOPRAM is not addictive. However, if you suddenly stop taking it, you may get side effects.</p><p><strong>Tell your doctor is you get any side effects after stopping APO-ESCITALOPRAM.</strong></p><p>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking APO-ESCITALOPRAM.</p><p>It helps most people with depression, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder, but it may have unwanted side effects in a few people.</p><p>The side effects of APO-ESCITALOPRAM are, in general, mild and disappear after a short period of time.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you notice any of the following and they worry you:</p><ul><li>decreased appetite or loss of appetite</li><li>dry mouth</li><li>diarrhoea</li><li>nausea (feeling sick)</li><li>sleeplessness</li><li>fatigue, sleepiness or drowsiness, yawning</li><li>increased&nbsp; sweating</li><li>sexual disturbances (decreased sexual drive; problems with ejaculation or erection; women may experience difficulties achieving orgasm).</li></ul><p>&nbsp;</p><p>Tell your doctor as soon as possible if you notice any of the following:</p><ul><li>agitation, confusion, panic attacks*, anxiety</li><li>dizziness</li><li>dizziness when you stand up due to low blood pressure*</li><li>low sodium levels in the blood (the symptoms are feeling sick and unwell with weak muscles or feeling confused)*</li><li>abnormal liver function tests (increased amount of liver enzymes in the blood)*</li><li>difficulties urinating*</li><li>unusual secretion of breast milk*</li><li>increased tendency to develop bruises*</li><li>rash, itching, patches of circumscribed&nbsp; swellings.</li></ul><p>&nbsp;</p><p>These may be serious side effects of APO-ESCITALOPRAM. You may need urgent medical attention. Tell your doctor immediately, or go to Accident and Emergency at your nearest hospital, if you notice any of the following:</p><ul><li>serious allergic reaction (symptoms of an allergic reaction may include swelling of the face, lips, mouth of throat which may cause difficulty in swallowing or breathing, or hives)</li><li>high fever, agitation, confusion, trembling and abrupt contractions of muscles (these symptoms may be signs of a rare condition called serotonin syndrome)*</li><li>mania*, hallucinations</li><li>seizures, tremors, movement disorders (involuntary movements of the muscles)*.</li></ul><p>&nbsp;</p><p>These are very serious side effects. You may need urgent medical attention or hospitalisation.</p><p>The side effects marked with an asterisk (*) are a number of rare side effects that are known to occur with medicines that work in a similar way to APO-ESCITALOPRAM.</p><p>Tell your doctor if you notice anything else that is making you feel unwell.&nbsp; Other side effects not listed above may occur in some people.</p><p>Ask your doctor or pharmacist to answer any questions you may have. Do not be alarmed by this list of possible side effects. You may not experience any of them.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep it where children cannot reach it.</p><p>- A locked cupboard at least one&shy; and-a-half metres above the ground is a good place to store medicines.</p><p>- Keep APO-ESCITALOPRAM tablets in its original packaging until it is time to take them.</p><p>- If you take the tablets out of the original packaging, they will not keep well.</p><p>- Keep APO-ESCITALOPRAM in a cool dry place below 30&deg;C.</p><p>- Do not leave it in the car.</p><p>- Do not store APO-ESCITALOPRAM or any other medicine in the bathroom, near a sink, or on a window-sill.</p><p>- Heat and dampness can destroy some medicines.</p><p>- Disposal: If your doctor tells you to stop taking APO-ESCITALOPRAM, or the medicine has passed its expiry date, ask your pharmacist what to do with any that are left over. Return any unused medicine to your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substances are escitalopram oxalate.</li><li>The other ingredients are Lactose, cellulose-microcrystalline, croscarmellose sodium, butylated hydroxyanisole, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol 8000 &amp; titanium dioxide.</li></ul><p>APO-ESCITALOPRAM does not contain gluten, tartrazine or any other azo dyes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                APO-ESCITALOPRAM tablets comes in 4 strengths:

5 mg tablets: white, round, biconvex, film-coated tablets, engraved "APO" on one side, "ESC" over "5" on the other side.

10 mg tablets: white, round, biconvex, film-coated tablets, engraved "APO" on one side, "ESC" over score "10" on the other side.

15 mg tablets: white, round, biconvex, film-coated tablets, engraved "APO" on one side, "ESC" over score "15" on the other side.

20 mg tablets: white, round, biconvex, film-coated tablets, engraved "APO" on one side, "ESC" over score "20" on the other side.

All strengths are available in blister packs of 30 tablets. 

* Not all strengths, pack types and/or pack sizes may be available.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Apotex Pty Ltd. 66 Waterloo Road North Ryde NSW Australia</p><p><strong>Manufacturer </strong></p><p>Apotex Inc. 150 signet Toronto, Ontario M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 03/2015.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong><u>أ- </u></strong><strong><u>كيفية عمل هذا الدواء</u></strong></p><p dir="RTL">إن اسم الدواء الذي بين يديك هو ابو-اسيتالوبرام. وهو يحتوي على المادة الفعالة أوكسالات اسيتالوبرام. ويستخدم ابو-اسيتالوبرام لعلاج الاكتئاب. وهو ينتمي إلى مجموعة من الأدوية تسمى مثبطات إعادة امتصاص السيروتونين الانتقائية (إس إس آر آي إس). ويعتقد أنها تعمل عن طريق تأثيرها على مواد كيميائية بالمخ تسمى أمينات والمسئولة عن تنظيم الحالة المزاجية. والاكتئاب أطول أمدا أو أشد قسوة من انخفاض الحالات المزاجية التي تعتري أي شخص من وقت لآخر بسبب ضغوط الحياة اليومية. ويعتقد أن سببه عدم التوازن الكيميائي في أجزاء من المخ. ويؤثر هذا الاختلال على الجسد بالكامل ويمكن أن يتسبب في أعراض نفسية وبدنية كالشعور بانخفاض الحيوية وفقدان الاستمتاع بالأنشطة وعدم القدرة على الاستمتاع بالحياة وفقدان الشهية أو الإفراط في تناول الطعام واضطرابات في النوم وفي كثير من الأحيان الاستيقاظ مبكرا وفقدان الدافع الجنسي وفقدان الطاقة والشعور بالذنب على لاشيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ب- </u></strong><strong><u>في ماذا يستعمل هذا الدواء</u></strong></p><p dir="RTL">ويمكن لعقار ابو-اسيتالوبرام أن يصلح ذلك الاختلال الكيميائي وربما يساعد في تخفيف أعراض الاكتئاب. ويستخدم ابو-اسيتالوبرام لعلاج المرضى الذين كثيرا ما&nbsp; يتجنبون و/أو يخافون المواقف الاجتماعية. ويمكن استخدام ابو-اسيتالوبرام لعلاج المرضى الذين يعانون من القلق المفرط والاضطراب. كما يمكن استخدام ابو-اسيتالوبرام لعلاج الخوف الغير منطقي أو التصرفات الوسواسية (الوسواس القهري). الوسواس القهري يشمل وجود كلا من الوساوس والأفعال القهرية. والوساوس هي أفكار غير مرغوبة تحدث مرارا وتكرارا. والأفعال القهرية هي الحاجة المستمرة لتكرار أعمال معينة نتيجة لهذه الأفكار.</p><p dir="RTL">وعلى الرغم من ذلك فقد يصف طبيبك ابو-اسيتالوبرام لسبب آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>أ- لا تستخدم ابو-اسيتالوبرام</u></strong></p><ul dir="rtl"><li><strong>لا تتناول ابو-اسيتالوبرام إذا كنت قد أصبت من قبل بتفاعل حساسية له أو لأي دواء آخر يحتوي على سيتالوبرام أو أي من المكونات المذكورة في آخر هذه النشرة</strong>.</li><li><strong>لا تتناول ابو-اسيتالوبرام إذا كنت مصاباً بعدم التحمل أو الحساسية للاكتوز حيث تحتوي أقراص ابو-اسيتالوبرام على اللاكتوز. </strong>وتتضمن أعراض تفاعل الحساسية ضيق في التنفس أو أزيز عند التنفس أو صعوبة في التنفس, وتورم بالوجه أو الشفاه أو اللسان أو أجزاء أخرى من الجسم أو طفح جلدي أو حكة أو بثور على الجلد.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><ul dir="rtl"><li><strong>لا تتناول ابو-اسيتالوبرام في نفس الوقت مع الأدوية التالي ذكرها: </strong><ul><li>بيموزيد وهو عقار يستخدم لعلاج الأمراض العقلية.</li><li>مثبطات الإنزيم المؤكسد أحادي الأمين والتي تستخدم أيضا لعلاج الاكتئاب</li></ul></li><li>لا تتناول ابو-اسيتالوبرام أثناء تناولك مثبطات الإنزيم المؤكسد أحادي الأمين أو إذا كنت قد تناولت إحداها خلال الأربعة عشر يوماً الأخيرة. إن تناول ابو-اسيتالوبرام مع مثبطات الإنزيم المؤكسد أحادي الأمين قد ينتج عنه تفاعل خطير يصحبه ارتفاع مفاجئ في درجة حرارة الجسم وارتفاع شديد في ضغط الدم وتشنجات عنيفة. وسوف يعرفك طبيبك المعالج متى يكون البدء بتناول ابو-اسيتالوبرام آمناً بعد إيقاف مثبط الإنزيم المؤكسد أحادي الأمين.</li><li><strong>لا تقدم على تناول ابو-اسيتالوبرام بعد انتهاء تاريخ الصلاحية (</strong><strong>EXP</strong><strong>) المطبوع على العبوة</strong>. فربما لا يعمل هذا الدواء جيدا إذا تناولته بعد مرور تاريخ الصلاحية.</li><li><strong>لا تتناول ابو-اسيتالوبرام إذا تمزقت العبوة أو ظهر عليها آثار العبث. </strong>أذا انتهى تاريخ الصلاحية أو تلفت العبوة قم بردها إلى الصيدلي للتخلص منها.</li><li><strong>لا تعطي الأقراص لأي شخص آخر حتى ولو كان يعاني من نفس حالتك.</strong></li><li><strong>لا تتناول ابو-اسيتالوبرام لعلاج أي شكاوى أخرى إلا بعد إخبار طبيبك.</strong></li></ul><p>&nbsp;</p><p dir="RTL"><strong><u>ب- الاحتياطات عند الاستعمال</u></strong></p><p dir="RTL"><strong>قبل البدء في تناوله أخبر طبيبك :</strong></p><ul dir="rtl"><li><strong>إذا كنت مصاباً بالحساسية لأي مواد أخرى كالأطعمة والمواد الحافظة والصبغات.</strong></li><li><strong>إذا كنت مصاباً أو سبقت إصابتك بأي من الحالات المرضية التالية:</strong><ul><li>اعتلال نزفي</li><li>مرض السكري</li><li>مرض بالقلب</li><li>مرض بالكلى</li><li>مرض بالكبد</li><li>الاضطراب المزاجي ثنائي القطبية (الاكتئاب الجنوني)</li><li>تاريخ مرضي للإصابة بالتشنجات أو النوبات الصرعية</li></ul></li></ul><p dir="RTL">&nbsp;</p><ul dir="rtl"><li><strong>لا تقدم على إعطاء ابو-اسيتالوبرام للأطفال والمراهقين </strong>ليست هناك خبرة متاحة فيما يتعلق باستخدامه مع الأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة.</li><li>يمكن أن يوصف ابو-اسيتالوبرام للمرضى المسنين الذين تزيد أعمارهم على 65 سنة بجرعة منخفضة. فتأثير ابو-اسيتالوبرام لدى المرضى المسنين يشبه تأثيره لدى غيرهم من المرضى.</li><li><strong>إذا لم تكن قد أبلغت طبيبك المعالج بأي مما سبق، فبادر بإخباره قبل أن تشرع في تناول ابو-اسيتالوبرام</strong>.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ت- الحمل والرضاعة</u></strong></p><p dir="RTL">لا تتناولي ابو-اسيتالوبرام إذا كنت حاملا إلا إذا ناقشت مع طبيبك المخاطر والفوائد المحتملة. فقد تتأثر الحالة العامة لمولودك بأدوية مثل ابو-اسيتالوبرام.</p><p dir="RTL">لا تتناولي ابو-اسيتالوبرام إذا كنت ترضعين طفلك رضاعة طبيعية إلا إذا ناقشت مع طبيبك المخاطر والفوائد المحتملة. فلا ينصح بالرضاعة الطبيعية أثناء تناولك ابو-اسيتالوبرام لأنه يفرز في لبن الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ث- تأثيره</u></strong><strong><u> على القيادة واستخدام الآلات</u></strong></p><p dir="RTL">كن حذرا أثناء القيادة أو تشغيل الآلات إلى أن تعرف مدى تأثير ابو-اسيتالوبرام عليك. قد يسبب ابو-اسيتالوبرام الغثيان والإرهاق والدوار لدى بعض الأشخاص خاصة في بداية العلاج. فإذا تعرضت لأي من هذه الأعراض، تجنب القيادة أو تشغيل الآلات أو عمل أي شيء آخر قد يمثل خطورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ج- التفاعلات مع هذا الدواء</u></strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى بما في ذلك الأدوية التي تشتريها بدون وصفة طبية من الصيدلية أو السوبر ماركت أو </strong>محلات الأغذية الصحية.</p><p dir="RTL">قد تتعارض بعض الأدوية مع ابو-اسيتالوبرام وتشمل:</p><ul dir="rtl"><li>بوبروبريون وهو عقار يساعد في علاج إدمان النيكوتين.</li><li>&nbsp;الأدوية المستخدمة لعلاج الارتجاع والقرح مثل سيميتيدين و إزومبرازول ولانسوبرازول.</li><li>الأدوية المعروفة بأنها تطيل زمن النزيف مثل الأسبرين ومضادات الالتهاب غير الاستيرويدية.</li><li>&nbsp;تكلوبيدين و وارفارين، وهما عقاران يستخدمان للوقاية من تجلط الدم.</li><li>مفلوكين، وهو عقار مضاد للملاريا.</li><li>سوماتريبتان, المستخدم لعلاج حالات الشقيقة.</li><li>ترامادول , المستخدم لتخفيف الآلام.</li><li>العقاقير التي تؤثر على المواد الكيميائية بالمخ.</li><li>بعض أدوية القلب مثل فليكاينيد وبروبافينون وميتوبرولول.</li><li>تريبتوفان, حمض أميني.</li><li>ليثيوم, يستخدم لعلاج التقلبات المزاجية وبعض أنواع الاكتئاب.</li><li>مضادات الذهان, وهي مجموعة من الأدوية تستخدم لعلاج بعض الحالات العقلية والعاطفية مثل ريسبريدون و ثيوريدازين و هالوبيريدول.</li><li>مضادات الاكتئاب ثلاثية الحلقات مثل إميبرامين و ديسيبرامين.</li><li>نبتة سانت جون (هيبريكوم برفوراتوم)، وهي علاج عشبي.</li><li>أي أدوية أخرى للاكتئاب أو القلق أو الوسواس القهري أو الاضطرابات المزاجية التي تسبق الحيض.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتأثر هذه الأدوية بعقار ابو-اسيتالوبرام أو قد تؤثر على كفاءة عمله. وقد تحتاج إلى كميات مختلفة من علاجك أو إلى تناول أدوية أخرى. وسوف ينصحك طبيبك بذلك. ولدى طبيبك أو الصيدلي المزيد من المعلومات عن الأدوية التي ينبغي توخى الحذر بشأنها أو تجنب تناولها مع ابو-اسيتالوبرام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تجنب الكحول أثناء تناولك لهذا الدواء </strong>لا ينصح بشرب الكحول أثناء علاجك من الاكتئاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اتبع كل توجيهات الطبيب أو الصيدلي بعناية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أ- ما هي الكمية التي تستخدم ل</u></strong><strong><u>ابو-اسيتالوبرام</u></strong></p><p dir="RTL">سيقوم طبيبك بتحديد الجرعة. إن الجرعة القياسية لهذا الدواء هي 10 ملجم يوميا وقد يزيدها طبيبك إلى 20 ملجم يوميا.الجرعة القصوى الموصى بها هي 10 ملجم يوميا. وينصح بتناول جرعة مبدئية 5 ملجم يوميا لأول أسبوعين بالنسبة للمرضى الذين يعانون من مرض بالكبد. وقد يزيد طبيبك الجرعة إلى 10 ملجم يوميا. وقد يصف طبيبك جرعات مختلفة. <strong>قم باستشارة طبيبك أو الصيدلي إذا كنت غير متأكد من الجرعة الصحيحة. </strong>وسوف يخبراك بمقدار الجرعة التي ينبغي أن تتناولها بالضبط.<strong>اتبع التعليمات التي يعطونك إياها </strong>إذا تناولت جرعة خاطئة فإن ابو-اسيتالوبرام قد لا يعمل بكفاءة وقد لا تتحسن حالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ب- كيف ومتى يستخدم </u></strong><strong><u>ابو-اسيتالوبرام</u></strong></p><p dir="RTL">ابتلع الأقراص كاملة مع كوب كامل من الماء. لا تمضغها. تناول ابو-اسيتالوبرام كجرعة واحدة إما في الصباح أو في المساء. تناول ابو-اسيتالوبرام مع الطعام أو بدونه. <strong>استمر في تناول ابو-اسيتالوبرام حتى ولو استغرق الأمر بعض الوقت قبل الشعور بأي تحسن في حالتك. </strong>كما هو الحال مع غيره من الأدوية المستخدمة في علاج تلك الحالات، فقد يستغرق الأمر بضعة أسابيع قبل الشعور بأي تحسن ويتفاوت الأفراد تفاوتاً كبيرا في استجابتهم لعقار ابو-اسيتالوبرام. وسوف يتبين طبيبك مدى تقدمك على فترات زمنية منتظمة. وقد تتفاوت فترات العلاج بين الأفراد ولكن لا تقل عادة عن 6 اسابيع. وفي بعض الحالات، قد يقرر الطبيب ضرورة العلاج لفترة أطول. <strong>استمر في تناول الدواء طالما أخبرك بذلك الطبيب حتى ولو شعرت بالتحسن. </strong>قد يستمر المرض الأصلي لفترة طويلة وقد تعاودك الأعراض إذا توقفت عن العلاج على نحو مبكر. <strong>لا تتوقف عن تناول الدواء بشكل مفاجئ. </strong>سيخبرك طبيبك عن كيفية تقليل الجرعة لتتجنب الآثار الجانبية الغير مرغوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ت- الجرعة الزائدة</u></strong></p><p dir="RTL">عليك الاتصال تليفونياً على الفور بطبيبك أو بمركز معلومات السموم أو الذهاب إلى قسم الحوادث والطوارئ في أقرب مستشفى، إذا كنت تعتقد أنك أو أي شخص آخر تناول ابو-اسيتالوبرام بجرعة مفرطة. بادر بذلك وإن لم تظهر أية علامات على عدم الارتياح أو التسمم. قد تحتاج إلى رعاية طبية عاجلة. قد تشتمل أعراض الجرعة المفرطة على الشعور بدوار وانخفاض في ضغط الدم والغثيان (الشعور بالرغبة في التقيؤ) والتقيؤ والإثارة والرعشة (الاهتزاز) ونادرا التشنجات والغيبوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ث- الجرعة الفائتة</u></strong></p><p dir="RTL">إذا فاتتك جرعة وتذكرتها خلال أقل من 12 ساعة، فبادر بتناولها فورا ثم عد إلى تناول الدواء كما كنت تفعل عادة. أما إذا كان موعد&nbsp; تناول الجرعة التالية قد أصبح وشيكاً، فعليك تخطي الجرعة الفائتة وتناول الجرعة التالية في وقتها. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها. قم باستشارة طبيبك إذا لم تكن متأكدا مما يجب القيام به. إذا كان لديك صعوبة في تذكر موعد تناول الدواء، اطلب من الصيدلي بعض النصائح.</p><p dir="RTL"><strong>لا تتوقف عن تناول ابو-اسيتالوبرام أو تقلل الجرعة بدون مراجعة الطبيب.</strong></p><p dir="RTL"><strong>لا تدع الدواء ينفد لديك في أيام الأجازات والعطلات الأسبوعية.</strong></p><p dir="RTL">قد يسبب التوقف المفاجئ عن تناول ابو-اسيتالوبرام أعراض التوقف الغير مرغوبة كالدوار والصداع والغثيان. وسوف يخبرك الطبيب عن وقت وكيفية إيقاف ابو-اسيتالوبرام. سيقوم طبيبك بتقليل الجرعة التي تتناولها تدريجيا على مدى أسبوع إلى أسبوعين قبل التوقف نهائيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ج- عند استخدام ابو-اسيتالوبرام</u></strong></p><p dir="RTL">إذا كنت على وشك أن تبدأ في تناول أي دواء جديد، فقم بتذكير طبيبك أو الصيدلي أنك تتناول ابو-اسيتالوبرام. أخبر من يقومون بعلاجك من أطباء آخرين أو أطباء الأسنان أو الصيادلة بأنك تتناول هذا الدواء.</p><p dir="RTL">إذا أصبحت حاملا أثناء تناولك ابو-اسيتالوبرام، قومي بإخبار طبيبك فوراً.</p><p dir="RTL">أبلغ طبيبك فوراً إذا تبادرت إليك أي أفكار انتحارية أو أي تغيرات مزاجية أو نفسية. ويجب اتخاذ كل ذكر للانتحار أو العنف بجدية.</p><p dir="RTL"><strong>إذا ظهرت عليك أو على أي شخص تعرفه أي من العلامات التحذيرية التالي ذكرها والخاصة بالسلوك المتعلق بالانتحار خلال فترة تناول ابو-اسيتالوبرام، فبادر بإبلاغ مقدم الرعاية الصحية على الفور أو حتى بالذهاب إلى أقرب مستشفى لتلقي العلاج</strong>:</p><ul dir="rtl"><li>الأفكار أو الحديث عن الموت أو الانتحار</li><li>الأفكار أو الحديث عن إيذاء النفس أو إيذاء الآخرين</li><li>أي محاولات لأذى النفس في الآونة الأخيرة</li><li>الزيادة في السلوك العدواني أو سرعة الانفعال أو الهياج.</li></ul><p dir="RTL"><strong>إذا تعرضت لنوبة من الهوس، قم بإبلاغ طبيبك في أقرب وقت ممكن.</strong></p><p dir="RTL">وقد يدخل بعض المرضى الذين يعانون من الاضطراب المزاجي ثنائي القطبية (الاكتئاب الجنوني) في مرحلة جنونية والتي تتميز بأفكار غزيرة سريعة التغير والابتهاج المبالغ فيه والنشاط البدني المفرط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جميع الأدوية قد يكون لها آثار جانبية غير مرغوب فيها والتي قد تكون خطيرة في بعض الأحيان ولكنها لا تكون كذلك في معظم الوقت. وسوف يقوم الطبيب بتقييم مخاطر تناول هذا الدواء في مقابل الفوائد التي يتوقعها/ تتوقعها لك.</p><p dir="RTL">إن ابو-اسيتالوبرام لا يسبب الإدمان ولكن قد تتعرض إلى بعض الآثار الجانبية إذا توقفت عن تناوله بشكل مفاجئ.</p><p dir="RTL"><strong>بادر بإبلاغ طبيبك إذا تعرضت لأي من الآثار الجانبية عقب إيقاف ابو-اسيتالوبرام.</strong></p><p dir="RTL">قم بإخبار الطبيب أو الصيدلي في أقرب وقت ممكن إذا شعرت بسوء أثناء تناولك ابو-اسيتالوبرام.</p><p dir="RTL">إنه يساعد معظم الأشخاص الذين يعانون من الاكتئاب ومرض القلق الاجتماعي (الرهاب الاجتماعي) والقلق المرضي العام والوسواس القهري ولكن قد يكون له بعض الآثار السلبية لدى بعض الناس.</p><p dir="RTL">وعلى العموم&nbsp; فالآثار الجانبية لعقار ابو-اسيتالوبرام تكون بسيطة وتختفي بعد فترة وجيزة من الوقت.</p><p dir="RTL">قم بإخبار الطبيب أو الصيدلي إذا لاحظت أيا من الأعراض التالية وقد أقلقتك:</p><ul dir="rtl"><li>قلة أو فقدان الشهية</li><li>جفاف الفم</li><li>الإسهال</li><li>الغثيان (الشعور بالرغبة في التقيؤ)</li><li>الأرق</li><li>الإرهاق والنعاس أو الدوخة والتثاؤب</li><li>زيادة التعرق</li><li>الاضطرابات الجنسية (انخفاض الشهوة الجنسية؛ اضطرابات في الانتصاب أو القذف؛ وقد توجه النساء صعوبة في الوصول إلى النشوة الجنسية).</li></ul><p dir="RTL">قم بإبلاغ طبيبك في أقرب وقت ممكن إذا لاحظت أيا من الآتي:</p><ul dir="rtl"><li>الإثارة والاختلاط ونوبات من الذعر* والقلق</li><li>الدوار</li><li>الدوار عند الوقوف بسبب انخفاض ضغط الدم*</li><li>انخفاض مستوى الصوديوم في الدم (وأعراضه هي الشعور بالإعياء واعتلال الصحة مع وهن العضلات أو الشعور بالاختلاط) *</li><li>اختبارات وظائف الكبد غير طبيعية (زيادة كمية انزيمات الكبد في الدم) *</li><li>صعوبات في التبول*</li><li>الإفراز الغير معتاد للبن الثدي*</li><li>زيادة القابلية لحدوث الكدمات*</li><li>طفح جلدي وحكة وبقع لتورمات محددة</li></ul><p>&nbsp;</p><p dir="RTL">قد تكون هذه أعراضاً جانبية خطيرة لعقار ابو-اسيتالوبرام. وقد تحتاج إلى رعاية طبية عاجلة.</p><p dir="RTL">أبلغ طبيبك مباشرة أو توجه إلى قسم الحوادث والطوارئ في أقرب مستشفى إذا لاحظت أيا من الآتي:</p><ul dir="rtl"><li>تفاعل حساسية شديد ( وقد تشتمل أعراض تفاعلات الحساسية على تورم الوجه أو الشفتين أو الفم&nbsp; أو الحلق مما قد يسبب صعوبة في البلع والتنفس، أو ظهور بثور)</li><li>الحمى الشديدة والهياج والاختلاط والرعشة والانقباضات العضلية المفاجئة ( قد تكون تلك الأعراض هي علامات لحالة نادرة تسمى متلازمة السيروتونين) *</li><li>الجنون* والهلوسة</li><li>التشنجات والرعشة واضطرابات الحركة (الحركة اللاإرادية للعضلات) *</li></ul><p dir="RTL">هذه أعراض جانبية خطيرة جدا وقد تحتاج إلى رعاية طبية عاجلة أو تنويم بالمستشفى.</p><p dir="RTL">إن الآثار الجانبية المشار إليها بعلامة النجمة (*) تمثل عدداً من الآثار الجانبية النادرة والمعروف أنها تحدث مع الأدوية التي تعمل بطريقة مماثلة لعقار ابو-اسيتالوبرام.</p><p dir="RTL">أبلغ طبيبك إذا لاحظت أي شيء آخر يجعلك تشعر بالإعياء قد تحدث بعض الآثار الجانبية غير المذكورة أعلاه لدى بعض الأشخاص. اطلب من الطبيب أو الصيدلي الإجابة عن أي استفسارات لديك. لا تنزعج بهذه القائمة من الأعراض الجانبية المحتملة قد لا تصيبك أي منها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يحفظ بعيدا عن متناول أيدي الأطفال.</p><p dir="RTL">- يحسن حفظ الأدوية في دولاب مغلق على ارتفاع متر ونصف من الأرض على الأقل.</p><p dir="RTL">- تحفظ أقراص ابو-اسيتالوبرام في عبوتها الأصلية إلى أن يحين وقت تناولها.</p><p dir="RTL">- إذا أخرجت الأقراص من عبوتها الأصلية، فلن تظل بحالة جيدة.</p><p dir="RTL">- يحفظ ابو-اسيتالوبرام في مكان بارد جاف حيث لا تزيد درجة الحرارة عن 30 درجة مئوية.</p><p dir="RTL">- لا تتركه في السيارة</p><p dir="RTL">- لا يحفظ&nbsp; ابو-اسيتالوبرام أو أي دواء آخر في دورة المياه أو قريباً من الحوض أو على عتبة النافذة.</p><p dir="RTL">- قد تتلف الحرارة والرطوبة بعض الأدوية.</p><p dir="RTL">- التخلص من الدواء: إذا أخبرك طبيبك بالتوقف عن تناول ابو-اسيتالوبرام أو إذا انتهت مدة صلاحية الدواء، فاسأل الصيدلي الذي تتعامل معه عما يجب القيام به حيال أي كمية متبقية. قم بإعادة أي دواء غير مستخدم إلى الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>المادة الفعالة هي أوكسالات اسيتالوبرام.</li><li>المواد الاخرى هي لاكتوز، سليولوز دقيق التبلر، كروسكارميلوز الصوديوم، بيوتيلات هيدروكسي أنيزول، سترات الماغنسيوم، هايبرميلوز، هيدروكسي بروبيل سليولوز، ماكروجول 8000، ثاني أكسيد التايتانيوم.</li></ul><p dir="RTL">لا يحتوي ابو-اسيتالوبرام على جلوتين أو ترترازين أو غيرها من صبغات آزو.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص ابو-اسيتالوبرام في أربع تركيزات:</p><ul dir="rtl"><li>أقراص 5 ملجم : أقراص بيضاء مستديرة ثنائية التحدب مغلفة بطبقة رقيقة ومحفور &quot;APO&quot; على أحد جانبي القرص و &quot;ESC&quot; فوق &quot;5&quot; على الجانب الآخر.</li><li>أقراص 10 ملجم : أقراص بيضاء مستديرة ثنائية التحدب مغلفة بطبقة رقيقة ومحفور &quot;APO&quot; على أحد جانبي القرص و &quot;ESC&quot; فوق العلامة &quot;10&quot; على الجانب الآخر.</li><li>أقراص 15 ملجم : أقراص بيضاء مستديرة ثنائية التحدب مغلفة بطبقة رقيقة ومحفور &quot;APO&quot; على أحد جانبي القرص و &quot;ESC&quot; فوق العلامة &quot;15&quot; على الجانب الآخر.</li><li>أقراص 20 ملجم : أقراص بيضاء مستديرة ثنائية التحدب مغلفة بطبقة رقيقة ومحفور &quot;APO&quot; على أحد جانبي القرص و &quot;ESC&quot; فوق العلامة &quot;20&quot; على الجانب الآخر.</li></ul><p dir="RTL">كل التركيزات متوفرة في عبوات أشرطة تحتوي على 30 قرص.</p><p dir="RTL">* قد لا يتم تسويق كل التراكيز والاحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">أبوتكس بتي لتد. 66 طريق واترلو نورث رايد &nbsp;إن اس دبليو استراليا.</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">شركة ابوتكس. 150 سيجنت في مدينة تورنتو، مقاطعة اونتاريو،M9L 1T9 &nbsp;كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 03/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ESCITALOPRAM TABLETS
Escitalopram oxalate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose, magnesium stearate, croscarmellose sodium, butylated hydroxyanisole, hypromellose, hydroxypropylcellulose, macrogol 8000 and titanium dioxide.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-Escitalopram 5 mg tablets
White, round, biconvex, film-coated tablets, engraved “APO” on one side, “ESC” over “5” on the other side.
Blister pack of 28 tablets – AUST R 146005. Bottle of 30 tablets – AUST R 146006.

APO-Escitalopram 10 mg tablets
White, round, biconvex, film-coated tablets, engraved “APO” on one side, “ESC” over score “10” on the other side.
Blister pack of 28 tablets – AUST R 146007. Bottle of 30 tablets – AUST R 146012.

APO-Escitalopram 15 mg tablets
White, round, biconvex, film-coated tablets, engraved “APO” on one side, “ESC” over score “15” on the other side.
Blister pack of 28 tablets – AUST R 146013. Bottle of 30 tablets – AUST R 146014.

APO-Escitalopram 20 mg tablets
White, round, biconvex, film-coated tablets, engraved “APO” on one side, “ESC” over score “20” on the other side.
Blister pack of 28 tablets – AUST R 146015. Bottle of 30 tablets – AUST R 146016.

* Not all strengths, pack types and/or pack sizes may be available.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depression.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong></p><p>Escitalopram is administered as a single oral dose and may be taken with or without food.</p><p>&nbsp;</p><p><u>Major Depression</u></p><p>The recommended dose is 10 mg (one 10 mg tablet) once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg (one 20 mg tablet) daily.</p><p>&nbsp;</p><p>Usually 2-4 weeks are necessary for antidepressant response, although the onset of therapeutic effect may be seen earlier. The treatment of a single episode of depression requires treatment over the acute and the medium term. After the symptoms resolve during acute treatment, a period of consolidation of the response is required. Therefore, treatment of a depressive episode should be continued for a minimum of 6 months.</p><p>&nbsp;</p><p><strong>Elderly Patients (&gt; 65 years of age)</strong></p><p>A longer half-life and a decreased clearance have been demonstrated in the elderly. 10 mg (one 10 mg tablet) is the recommended maximum maintenance dose in the elderly (see&nbsp;<strong>PHARMACOLOGY</strong>, Pharmacokinetics and <strong>PRECAUTIONS</strong>).</p><p>&nbsp;</p><p><strong>Children and Adolescents (&lt; 18 years of age)</strong></p><p>Safety and efficacy have not been established in this population. Escitalopram should not be used in children and adolescents under 18 years of age (see <strong>PRECAUTIONS</strong>).</p><p>&nbsp;</p><p><strong>Reduced Hepatic Function</strong></p><p>An initial dose of 5 mg (half a 10 mg tablet) daily for the first two weeks of treatment is recommended. Depending on individual patient response, the dose may be increased to 10 mg (one 10 mg tablet) (see <strong>PRECAUTIONS</strong>).</p><p>&nbsp;</p><p><strong>Reduced Renal Function</strong></p><p>Dosage adjustment is not necessary in patients with mild or moderate renal impairment. No information is available on the treatment of patients with severely reduced renal function (creatinine clearance &lt; 20 mL/min) (see <strong>PRECAUTIONS</strong>).</p><p>&nbsp;</p><p><strong>Poor Metabolisers of CYP2C19</strong></p><p>For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5 mg (half a 10 mg tablet) daily during the first two weeks of treatment is recommended. Depending on individual patient response, the dose may be increased to 10 mg (one 10 mg tablet) (see <strong>PHARMACOLOGY</strong>, <strong>Pharmacokinetics </strong>and <strong>PRECAUTIONS, Interactions with Other Medicines</strong>).</p><p>&nbsp;</p><p><strong>Discontinuation</strong></p><p>Significant numbers of discontinuation symptoms may occur with abrupt discontinuation of escitalopram. To minimise discontinuation reactions, tapered discontinuation over a period of at least one to two weeks is recommended. If unacceptable discontinuation symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the dose may be decreased but at a more gradual rate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to citalopram, escitalopram and any excipients in the Escitalopram tablets (see
PRESENTATIONS AND STORAGE CONDITIONS).


Monoamine Oxidase Inhibitors

Escitalopram should not be used in combination with monoamine oxidase inhibitors (MAOI) or the reversible MAOI (RIMA), moclobemide, or within 14 days of discontinuing treatment with a MAOI, and at least one day after discontinuing  treatment with the reversible MAOI (RIMA), moclobemide. Similarly, at least 14 days should be allowed after stopping escitalopram before starting a MAOI or RIMA. Cases of serious reactions, such as potentially life-threatening serotonin syndrome (characterised by neuromuscular excitation, altered mental status and autonomic dysfunction) have been reported in patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI) or the reversible MAOI (RIMA), moclobemide, and in patients who have recently discontinued an SSRI and have been started on a MAOI (see PRECAUTIONS, Interactions with Other Medicines).

Pimozide

Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS, Interactions with Other Medicines).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical</strong><strong> </strong><strong>Worsening</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Suicide</strong><strong> </strong><strong>Risk</strong></p><p>The risk of suicide attempt is inherent in depression and may persist until significant remission occurs. This risk must be considered in all depressed patients.</p><p>&nbsp;</p><p>Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored for clinical worsening and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not part of the patient&rsquo;s presenting symptoms.</p><p>&nbsp;</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms are present.</p><p>&nbsp;</p><p>Patients with co-morbid depression associated with other psychiatric disorders being treated with antidepressants should be similarly observed for clinical worsening and suicidality.</p><p>&nbsp;</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.</p><p>&nbsp;</p><p>Pooled analyses of 24 short-term (4 to 16-week), placebo-controlled trials of nine antidepressant medicines (SSRIs and others) in 4,400 children and adolescents with major depressive disorder (16 trials), obsessive-compulsive disorder (4 trials), or other psychiatric disorders (4 trials) have revealed a greater risk of adverse events representing suicidal behaviour or thinking (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients treated with an antidepressant was 4%, compared with 2% of patients given placebo. There was considerable variation in risk among the antidepressants, but there was&nbsp; a tendency towards an increase for almost all antidepressants studied. The risk of suicidality was most consistently observed in the major depressive disorder trials, but there were signals of risk arising from trials in other psychiatric indications (obsessive-compulsive disorder and social anxiety disorder) as well. No suicides occurred in these trials. It is unknown whether the suicidality risk in children and adolescent patients extends to use beyond several months. The nine antidepressant medicines in the pooled analyses included five SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) and four non-SSRIs (buproprion, mirtazapine, nefazodone, venlafaxine).</p><p>&nbsp;</p><p>Pooled analyses of short-term studies of antidepressant medications have also shown an increased risk of suicidal thinking and behaviour, known as suicidality, in young adults aged 18 to 24 years during initial treatment (generally the first one to two months). Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond the age of 24 years, and there was a reduction with antidepressants compared to placebo in adults aged 65 years and older.</p><p>&nbsp;</p><p>Symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adults, adolescents and children being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either worsening of depression and/or emergence of suicidal impulses has not been established, there is concern that such symptoms may be precursors of emerging suicidality.</p><p>&nbsp;</p><p>Families or caregivers of children and adolescents being treated with antidepressants for major depressive disorder or for any other condition (psychiatric or non-psychiatric) should be informed about the need to monitor these patients for the emergence of agitation, irritability, unusual changes in behaviour, and other symptoms described above, as well as the emergence of suicidality, and to report such symptoms to health care providers immediately. It is particularly important that monitoring be undertaken during the initial few months of antidepressant treatment or at times of dose increase or decrease.</p><p>&nbsp;</p><p>Prescriptions for escitalopram should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.</p><p>&nbsp;</p><p><strong>Akathisia / Psychomotor Restlessness</strong></p><p>The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&nbsp;</p><p><strong>Haemorrhage</strong></p><p>Bleeding abnormalities of the skin and mucous membranes have been reported with the use of SSRIs (including purpura, haematoma, epistaxis, vaginal bleeding and gastrointestinal bleeding). Escitalopram should therefore be used with caution in patients concomitantly treated with oral anticoagulants, medicinal products known to affect platelet function (e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti-inflammatory medicinal products (NSAIDs), ticlopidine and dipyridamole) as well as in patients with a past history of abnormal bleeding or those with predisposing conditions. Pharmacological gastroprotection should be considered for high risk patients.</p><p>&nbsp;</p><p><strong>Hyponatraemia</strong></p><p>Probably due to inappropriate antidiuretic hormone secretion (SIADH), hyponatraemia has been reported as a rare adverse reaction with the use of SSRIs. Especially elderly patients seem to be a risk group.</p><p>&nbsp;</p><p><strong>Seizures</strong></p><p>The drug should be discontinued in any patient who develops seizures. SSRIs should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. SSRIs should be discontinued if there is an increase in seizure frequency (see <strong>PRECAUTIONS</strong>, Pre-Clinical Safety).</p><p>&nbsp;</p><p><strong>Diabetes</strong></p><p>In patients&nbsp; with diabetes, treatment with an SSRI may alter glycaemic control, possibly due to improvement of depressive symptoms. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>&nbsp;</p><p><strong>Mania</strong></p><p>SSRIs should be used with caution in patients with a history of mania/hypomania. SSRIs should be discontinued in any patient entering a manic phase.</p><p>&nbsp;</p><p><strong>ECT (Electoconvulsive Therapy)</strong></p><p>There is limited published clinical experience of concurrent administration of SSRIs and ECT, therefore caution is advisable.</p><p>&nbsp;</p><p><strong>Effect on Ability to Drive and Use Machines</strong></p><p>Escitalopram does not impair intellectual function and psychomotor performance. However, as with other psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery.</p><p>&nbsp;</p><p><strong>Discontinuation</strong></p><p>Discontinuation symptoms when stopping treatment are common, particularly if discontinuation is abrupt.</p><p>&nbsp;</p><p>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.</p><p>&nbsp;</p><p>They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.</p><p>&nbsp;</p><p>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that escitalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><strong>Cardiac Disease</strong></p><p>Escitalopram has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Like other SSRIs, escitalopram causes a small decrease in heart rate. Consequently, caution should be observed when escitalopram is initiated in patients with pre-existing slow heart rate.</p><p>&nbsp;</p><p><strong>Impaired Hepatic Function</strong></p><p>In subjects with hepatic impairment, clearance of escitalopram was decreased and plasma concentrations were increased. The dose of escitalopram in hepatically impaired patients should therefore be reduced (see <strong>PHARMACOLOGY</strong>, Pharmocokinetics and <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><strong>Impaired Renal Function</strong></p><p>Escitalopram is extensively metabolised and excretion of unchanged drug in urine is a minor route of elimination. At present no information is available for the treatment of patients with severely reduced renal function (creatinine clearance &lt; 20 mL/min) and escitalopram should be used with caution in such patients (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><strong>Pre-Clinical Safety</strong></p><p>High doses of escitalopram, which resulted in plasma Cmax&nbsp;for escitalopram and metabolites at least 8-fold greater than anticipated clinically, have been associated with convulsions, ECG abnomalities and cardiovascular changes in experimental animals. Of the cardiovascular changes, cardiotoxicity (including congestive heart failure) was observed in comparative toxicological studies in rats following oral escitalopram or citalopram administration for 4 to 13 weeks and appears to correlate with peak plasma concentrations although its exact mechanism is not clear. Clinical experiences with citalopram, and the clinical trial experience with escitalopram, do not indicate that these findings have a clinical correlation</p><p>&nbsp;</p><p><strong>Paediatric Use (Children and Adolescents &lt; 18 years)</strong></p><p>The efficacy and safety of escitalopram has not been established in children and adolescents less than 18 years of age. Consequently, escitalopram should not be used in children and adolescents less than 18 years of age.</p><p>&nbsp;</p><p><strong>Use in the Elderly (&gt; 65 years)</strong></p><p>Escitalopram AUC and half-life were increased in subjects &ge; 65 years of age compared to younger subjects in a single-dose and a multiple-dose pharmacokinetic study. The dose of escitalopram in elderly patients should therefore be reduced (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><strong>Carcinogenicity</strong></p><p>No carcinogenicity studies were performed with escitalopram. However, other non-clinical studies suggest that the effects of escitalopram&nbsp; can be directly predicted from&nbsp; those of the citalopram racemate.</p><p>&nbsp;</p><p>Citalopram did not show any carcinogenic activity in long-term oral studies using mice and rats at doses up to 240 and 80 mg/kg/day, respectively.</p><p>&nbsp;</p><p><strong>Genotoxicity</strong></p><p>No genotoxicity studies were performed with escitalopram. However, other non-clinical studies suggest that the effects of escitalopram&nbsp; can be directly predicted from&nbsp; those of the citalopram racemate.</p><p>&nbsp;</p><p>In assays of genotoxic activity, citalopram showed no evidence of mutagenic or clastogenic activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>MAOIs</strong></p><p>Co-administration with MAO inhibitors may cause serotonin syndrome (see&nbsp;<strong>CONTRAINDICATIONS</strong>).</p><p>&nbsp;</p><p><em>Serotonin</em><em> </em><em>syndrome</em></p><p>Development of serotonin syndrome may occur in association with treatment with SSRIs and SNRIs, particularly when given in combination with MAOIs or other serotonergic agents. Symptoms and signs of serotonin syndrome include rapid onset of neuromuscular excitation (Hyperreflexia, incoordination, myoclonus, tremor), altered mental status (confusion, agitation, hypomania) and autonomic dysfunction (diaphoresis, diarrhoea, fever, shivering and rapidly fluctuating vital signs). Treatment with escitalopram should be discontinued if such events occur and supportive symptomatic treatment initiated.</p><p>&nbsp;</p><p><strong>Pimozide</strong></p><p>Co-administration of a single dose of pimozide 2 mg to subjects treated with racemic citalopram 40 mg/day for 11 days caused an increase in AUC and Cmax&nbsp;of pimozide, although not consistently throughout the study. The co-administration of pimozide and citalopram resulted in a mean increase in the QTc interval of approximately 10 msec. Due to the interaction with citalopram noted at a low dose of pimozide, concomitant administration of escitalopram and pimozide is contraindicated (see <strong>CONTRAINDICATIONS</strong>).</p><p>&nbsp;</p><p><strong>Serotonergic Drugs</strong></p><p>Co-administration with serotonergic drugs (e.g. tramadol, sumatriptan) may lead to an enhancement of serotonergic effects. Similarly, <em>Hypericum perforatum </em>(St John&rsquo;s Wort) should be avoided as adverse interactions have been reported with a range of drugs including antidepressants.</p><p>&nbsp;</p><p><strong>Lithium and Tryptophan</strong></p><p>There have been reports of enhanced effects when SSRIs have been given with lithium or tryptophan and therefore concomitant use of SSRIs with these drugs should be undertaken with caution.</p><p>&nbsp;</p><p><strong>Medicines Affecting the Central Nervous System</strong></p><p>Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs.</p><p>&nbsp;</p><p><strong>Medicines Lowering the Seizure Threshold</strong></p><p>SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold [e.g. antidepressants (tricyclics, SSRIs), neuroleptics (phenothiazines, thioxanthenes, butyrophenones), mefloquine, bupropion and tramadol].</p><p>&nbsp;</p><p><strong>Hepatic Enzymes</strong></p><p>Escitalopram has a low potential for clinically significant drug interactions. <em>In vitro </em>studies have shown that the biotransformation of escitalopram to its demethylated metabolites depends on three parallel pathways (cytochrome P450 (CYP) 2C19, 3A4 and 2D6). Escitalopram is a very weak inhibitor of isoenzyme CYP1A2, 2C9, 2C19, 2E1, and 3A4, and a weak inhibitor of 2D6.</p><p>&nbsp;</p><p><u>Effects of Other Drugs on Escitalopram <em>in vivo</em></u></p><p>The pharmacokinetics of escitalopram was not changed by co-administration with ritonavir (CYP3A4 inhibitor). Furthermore, co-administration with ketoconazole (potent CYP3A4 inhibitor) did not change the pharmacokinetics or racemic citalopram.</p><p>&nbsp;</p><p>Co-administration of escitalopram with omeprazole (a CYP2C19 inhibitor) resulted in a moderate (approximately 50%) increase in plasma concentrations of escitalopram and a small but statistically significant increase (31%) in the terminal half-life of escitalopram (see also <strong>DOSAGE AND ADMINISTRATION</strong>, Poor Metabolisers of CYP2C19).</p><p>&nbsp;</p><p>Co-administration of escitalopram with cimetidine (moderately potent general enzyme inhibitor) resulted in a moderate (approximately 70%) increase in the plasma concentrations of escitalopram.</p><p>&nbsp;</p><p>Thus, caution should be exercised at the upper end of the dose range of escitalopram when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, esomeprazole, fluoxetine, fluvoxamine, lansoprazole, and ticlopidine) or cimetidine. A reduction in the dose of escitalopram may be necessary based on clinical judgement (see also <strong>DOSAGE AND ADMINISTRATION</strong>, Poor Metabolisers of CYP2C19).</p><p>&nbsp;</p><p><u>Effects of Escitalopram on Other Drugs <em>in vivo</em></u></p><p>Escitalopram is an inhibitor of the enzyme CYP2D6. Caution is recommended when escitalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortritypline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted.</p><p>&nbsp;</p><p>Co-administration with desipramine (a CYP2D6 substrate) resulted in a two-fold increase in plasma levels of desipramine. Therefore, caution is advised when escitalopram and desipramine are co-administered. A similar increase in plasma levels of desipramine, after administration of imipramine, was seen when given together with racemic citalopram.</p><p>&nbsp;</p><p>Co-administration with metoprolol (a CYP2D6 substrate) resulted in a two-fold increase in plasma levels of metoprolol. However, the combination had no clinically significant effects on blood pressure and heart rate.</p><p>&nbsp;</p><p>The pharmacokinetics of ritonavir (CYP3A4 inhibitor) was not changed by co-administration with escitalopram.</p><p>&nbsp;</p><p>Furthermore, pharmacokinetic interaction studies with racemic citalopram have demonstrated no clinically important interactions with carbamazepine (CYP3A4 substrate), triazolam &nbsp;(CY3A4 substrate),&nbsp; &nbsp;theophylline&nbsp; &nbsp;(CYP1A2&nbsp; &nbsp;substrate),&nbsp; &nbsp;warfarin&nbsp; &nbsp;(CYP3A4&nbsp; &nbsp;and&nbsp; &nbsp;CYP2C9&nbsp; &nbsp;substrate), levomepromazine (CYP2D6 inhibitor), lithium and digoxin.</p><p>&nbsp;</p><p><strong>Medicines that Interfere with Haemostasis (NSAIDs, Aspirin, Warfarin, etc)</strong></p><p>Serotonin release by platelets&nbsp; plays an important role in haemostasis. There is&nbsp; an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of abnormal bleeding. Concurrent use of an NSAID, aspirin or warfarin potentiates this risk. Thus, patients should be cautioned about using such medicines concurrently with escitalopram.</p><p>&nbsp;</p><p><strong>Alcohol</strong></p><p>The combination of SSRIs and alcohol is not advisable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects on Fertility</strong></p><p>No fertility studies were performed with escitalopram. However, other non-clinical studies suggest that the effects of escitalopram can be directly predicted from those of citalopram racemate.</p><p>&nbsp;</p><p>In rats, female fertility was unaffected by oral treatment with citalopram doses which achieved plasma drug concentration slightly in excess of those expected in humans, but effects on male rat fertility have not been tested with adequate oral doses.</p><p>&nbsp;</p><p><strong>Use in Pregnancy (Category C)</strong></p><p>Limited clinical data are available regarding exposure to escitalopram during pregnancy.</p><p>&nbsp;</p><p>Neonates should be observed if maternal use of escitalopram continues into the later stages of pregnancy, particularly in the third trimester. If escitalopram is used until or shortly before birth, discontinuation effects in the newborn are possible. Abrupt discontinuation should be avoided during pregnancy.</p><p>&nbsp;</p><p>Neonates exposed to escitalopram, other SSRIs (Selective Serotonin Reuptake Inhibitors), or SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalisation, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. In the majority of cases, the complications begin immediately or soon (&lt; 24 hours) after delivery.</p><p>&nbsp;</p><p>Epidemiological data have shown that the use&nbsp; of SSRIS&nbsp; in pregnancy, particularly use in late pregnancy, was associated with an increased risk of persistent pulmonary&nbsp; hypertension of the newborn (PPHN). The risk of PPHN among infants born to women who used SSRIs late in pregnancy was estimated to be 4 to 5 times higher than the rate of 1 to 2 per 1000 pregnancies observed in the general population.</p><p>&nbsp;</p><p>Oral treatment of rats with escitalopram during organogenesis at maternotoxic doses led to increased post-implantation loss and reduced foetal weight at systemic exposure levels (based on AUC) ca. 11-fold that anticipated clinically, with no effects seen at 6-fold. No teratogenicity was evident in this study at relative systemic exposure levels of ca. 15 (based on AUC).</p><p>&nbsp;</p><p>There were no peri/postnatal effects of escitalopram following oral dosing of pregnant rats (conception through to weaning) at systemic exposure levels (based on AUC) ca. 2-fold than anticipated clinically. However, the number of stillbirths was increased and the size, weight and postnatal survival of offspring were decreased at a relative systemic exposure level ca. 5.</p><p>&nbsp;</p><p>Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed and only after careful consideration of the risk/benefit.</p><p>&nbsp;</p><p><em>Australian Categorisation Definition of Category C: </em>Drugs, which owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human foetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>It is expected that escitalopram, like citalopram, will be excreted into human breast milk. Studies in nursing mothers have shown that the mean combined dose of citalopram and demethylcitalopram transmitted to infants via breast milk (expressed as a percentage of the weight-adjusted maternal dose) is 4.4 &ndash; 5.1% (below the notional 10% level of concern).</p><p>&nbsp;</p><p>Plasma concentrations of these drugs in infants were very low or absent and there were no adverse effects. Whilst the citalopram data support the safety of use of escitalopram in breast-feeding women, the decision to breast-feed should always be made as an individual risk/benefit analysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Escitalopram does not impair intellectual function and psychomotor performance. However, as with other psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions observed with escitalopram are in general mild and transient. They are most frequent during the first one or&nbsp; two weeks of treatment and usually decrease in intensity and frequency with continued treatment and generally do not lead to a cessation of therapy. Data from short-term placebo-controlled studies are presented below. The safety data from the long-term studies showed a similar profile.</p><p>&nbsp;</p><p><strong>Treatment-Emergent Adverse Events with an Incidence of &ge; 1% in Placebo-Controlled Trials</strong></p><p>Figures marked with * in below table indicate adverse reactions where incidence with escitalopram is statistically significantly different from placebo (p &lt; 0.05).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>SYSTEM ORGAN CLASS AND PREFERRED TERM</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong><strong>PLACEBO</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>&nbsp;ESCITALOPRAM</strong></p></td></tr><tr><td style="text-align:center; vertical-align:top"><strong>n</strong></td><td style="text-align:center; vertical-align:top"><strong>(%)</strong></td><td style="text-align:center; vertical-align:top"><strong>n</strong></td><td style="text-align:center; vertical-align:top"><strong>(%)</strong></td></tr><tr><td style="vertical-align:top"><p>Patients Treated</p></td><td rowspan="1" colspan="2" style="text-align:center; vertical-align:top"><p>1795</p></td><td rowspan="1" colspan="2" style="text-align:center; vertical-align:top"><p>2632</p></td></tr><tr><td style="vertical-align:top"><p>Patients with Treatment Emergent Adverse Event</p></td><td style="vertical-align:top"><p>1135</p></td><td style="vertical-align:top"><p>(63.2)</p></td><td style="vertical-align:top"><p>1891</p></td><td style="vertical-align:top"><p>(71.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GASTROINTESTINAL</strong><strong> SYSTEM DISORDERS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>(8.4)</p></td><td style="vertical-align:top"><p>481</p></td><td style="vertical-align:top"><p>(18.3)*</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>(5.1)</p></td><td style="vertical-align:top"><p>207</p></td><td style="vertical-align:top"><p>(7.9)*</p></td></tr><tr><td style="vertical-align:top"><p>Mouth Dry</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>(4.1)</p></td><td style="vertical-align:top"><p>152</p></td><td style="vertical-align:top"><p>(5.8)*</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>(2.3)</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>(2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>(2.6)</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>(2.6)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>(1.6)</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>(2.1)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>(1.7)</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>(1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>(0.8)</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>(1.2)</p></td></tr></tbody></table><p>* = Statistically significant difference escitalopram vs. placebo (p &lt; 0.05).</p><p>[gs] = gender specific</p><p><img width="608" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1028" type="#_x0000_t75" style='width:455.15pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="text-align:center; vertical-align:top; width:329px"><p><strong>SYSTEM ORGAN CLASS AND PREFERRED TERM</strong></p></td><td rowspan="1" colspan="2" style="text-align:center; vertical-align:top; width:75px"><strong>PLACEBO</strong></td><td rowspan="1" colspan="2" style="text-align:center; vertical-align:top"><strong>ESCITALOPRAM</strong></td></tr><tr><td style="text-align:center; vertical-align:top; width:329px">&nbsp;</td><td style="text-align:center; vertical-align:top; width:26px"><strong>n</strong></td><td style="text-align:center; vertical-align:top"><strong>(%)</strong></td><td style="text-align:center; vertical-align:top"><strong>n</strong></td><td style="text-align:center; vertical-align:top"><strong>(%)</strong></td></tr><tr><td style="text-align:left; vertical-align:top; width:329px"><strong>CENTRAL</strong><strong> AND PERIPHERAL NERVOUS SYSTEM DISORDERS</strong></td><td style="vertical-align:top; width:26px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="text-align:left; vertical-align:top; width:329px"><p>Headache</p></td><td style="vertical-align:top; width:26px"><p>305</p></td><td style="vertical-align:top"><p>(17.0)</p></td><td style="vertical-align:top"><p>506</p></td><td style="vertical-align:top"><p>(19.2)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Dizziness</p></td><td style="vertical-align:top; width:26px"><p>64</p></td><td style="vertical-align:top"><p>(6.3)</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>(5.6)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Paraesthesia</p></td><td style="vertical-align:top; width:26px"><p>13</p></td><td style="vertical-align:top"><p>(0.7)</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>(1.3)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Migraine</p></td><td style="vertical-align:top; width:26px"><p>17</p></td><td style="vertical-align:top"><p>(0.9)</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>(0.8)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Tremor</p></td><td style="vertical-align:top; width:26px"><p>15</p></td><td style="vertical-align:top"><p>(0.8)</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>(1.3)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>PSYCHIATRIC DISORDERS</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Insomnia</p></td><td style="vertical-align:top; width:26px"><p>82</p></td><td style="vertical-align:top"><p>(4.6)</p></td><td style="vertical-align:top"><p>245</p></td><td style="vertical-align:top"><p>(9.3)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Somnolence</p></td><td style="vertical-align:top; width:26px"><p>62</p></td><td style="vertical-align:top"><p>(3.5)</p></td><td style="vertical-align:top"><p>217</p></td><td style="vertical-align:top"><p>(8.2)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Anorexia</p></td><td style="vertical-align:top; width:26px"><p>12</p></td><td style="vertical-align:top"><p>(0.7)</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>(2.1)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Libido decreased</p></td><td style="vertical-align:top; width:26px"><p>21</p></td><td style="vertical-align:top"><p>(1.2)</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>(3.9)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Anxiety</p></td><td style="vertical-align:top; width:26px"><p>44</p></td><td style="vertical-align:top"><p>(2.5)</p></td><td style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>(2.9)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Appetite decreased</p></td><td style="vertical-align:top; width:26px"><p>8</p></td><td style="vertical-align:top"><p>(0.5)</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>(1.3)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Agitation</p></td><td style="vertical-align:top; width:26px"><p>6</p></td><td style="vertical-align:top"><p>(0.3)</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>(1.3)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Nervousness</p></td><td style="vertical-align:top; width:26px"><p>13</p></td><td style="vertical-align:top"><p>(0.7)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>(1.0)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Dreaming Abnormal</p></td><td style="vertical-align:top; width:26px"><p>18</p></td><td style="vertical-align:top"><p>(1.0)</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>(1.6)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Impotence [gs]</p></td><td style="vertical-align:top; width:26px"><p>4</p></td><td style="vertical-align:top"><p>(0.6)</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>(2.2)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>RESPIRATORY</strong><strong> SYSTEM DISORDERS</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Upper Respiratory Tract Infection</p></td><td style="vertical-align:top; width:26px"><p>91</p></td><td style="vertical-align:top"><p>(5.1)</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>(3.6)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Coughing</p></td><td style="vertical-align:top; width:26px"><p>18</p></td><td style="vertical-align:top"><p>(1.1)</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>(0.9)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Rhinitis</p></td><td style="vertical-align:top; width:26px"><p>81</p></td><td style="vertical-align:top"><p>(4.8)</p></td><td style="vertical-align:top"><p>146</p></td><td style="vertical-align:top"><p>(5.5)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Sinusitis</p></td><td style="vertical-align:top; width:26px"><p>24</p></td><td style="vertical-align:top"><p>(1.3)</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>(1.7)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Pharyngitis</p></td><td style="vertical-align:top; width:26px"><p>44</p></td><td style="vertical-align:top"><p>(2.5)</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>(2.2)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Yawning</p></td><td style="vertical-align:top; width:26px"><p>3</p></td><td style="vertical-align:top"><p>(0.2)</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>(2.2)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Bronchitis</p></td><td style="vertical-align:top; width:26px"><p>31</p></td><td style="vertical-align:top"><p>(1.7)*</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>(0.9)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>BODY</strong><strong> </strong><strong>AS</strong><strong> </strong><strong>A WHOLE &ndash; GENERAL DISORDERS</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Influenza-like Symptoms</p></td><td style="vertical-align:top; width:26px"><p>65</p></td><td style="vertical-align:top"><p>(3.6)</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>(3.3)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Fatigue</p></td><td style="vertical-align:top; width:26px"><p>62</p></td><td style="vertical-align:top"><p>(3.5)</p></td><td style="vertical-align:top"><p>230</p></td><td style="vertical-align:top"><p>(8.7)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Back Pain</p></td><td style="vertical-align:top; width:26px"><p>61</p></td><td style="vertical-align:top"><p>(3.4)</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>(2.8)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>SKIN</strong><strong> AND APPENDAGES DISORDERS</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Sweating increased</p></td><td style="vertical-align:top; width:26px"><p>27</p></td><td style="vertical-align:top"><p>(1.5)</p></td><td style="vertical-align:top"><p>145</p></td><td style="vertical-align:top"><p>(5.5)*</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>MUSCULOSKELETAL</strong><strong> SYSTEM DISORDERS</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Arthralgia</p></td><td style="vertical-align:top; width:26px"><p>22</p></td><td style="vertical-align:top"><p>(1.2)</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>(1.0)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>REPRODUCTIVE</strong><strong> DISORDERS, FEMALE</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Anorgasmia [gs]</p></td><td style="vertical-align:top; width:26px"><p>3</p></td><td style="vertical-align:top"><p>(0.3)</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>(2.9)</p></td></tr><tr><td style="vertical-align:top; width:329px"><p><strong>METABOLIC</strong><strong> </strong><strong>AND</strong><strong> NUTRITIONAL DISORDERS</strong></p></td><td style="vertical-align:top; width:26px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:329px"><p>Weight increase</p></td><td style="vertical-align:top; width:26px"><p>20</p></td><td style="vertical-align:top"><p>(1.1)</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>(1.7)</p></td></tr><tr><td style="vertical-align:top; width:329px"><strong>REPRODUCTIVE</strong><strong> DISORDERS, MALE</strong></td><td style="vertical-align:top; width:26px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:329px">Ejaculation disorder [gs]</td><td style="vertical-align:top; width:26px">3</td><td style="vertical-align:top">(0.5)</td><td style="vertical-align:top">48</td><td style="vertical-align:top">(4.7)*</td></tr><tr><td style="vertical-align:top; width:329px">Ejaculation failure [gs]</td><td style="vertical-align:top; width:26px">1</td><td style="vertical-align:top">(0.2)</td><td style="vertical-align:top">27</td><td style="vertical-align:top">(2.7)*</td></tr><tr><td style="vertical-align:top; width:329px"><strong>CARDIOVASCULAR</strong><strong> DISORDERS</strong></td><td style="vertical-align:top; width:26px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:329px">Hypertension&nbsp;</td><td style="vertical-align:top; width:26px">24&nbsp;</td><td style="vertical-align:top">&nbsp;(1.3)*&nbsp;&nbsp;</td><td style="vertical-align:top">13</td><td style="vertical-align:top">(0.5)</td></tr><tr><td style="vertical-align:top; width:329px"><strong>HEART</strong><strong> RATE AND RHYTHM DISORDERS</strong></td><td style="vertical-align:top; width:26px">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top; width:329px">Palpitations</td><td style="vertical-align:top; width:26px">15</td><td style="vertical-align:top">(0.8)</td><td style="vertical-align:top">30</td><td style="vertical-align:top">(1.1)</td></tr><tr><td style="vertical-align:top; width:329px">Inflicted injury (unintended injury)</td><td style="vertical-align:top; width:26px">22</td><td style="vertical-align:top">(1.2)</td><td style="vertical-align:top">23</td><td style="vertical-align:top">(0.8)</td></tr></tbody></table><p>* = Statistically significant difference escitalopram vs. placebo (p &lt; 0.05).</p><p>[gs] = gender specific</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1050" style='width:455.15pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9103,12">
 <v:group id="_x0000_s1051" style='position:absolute;left:6;top:6;width:9092;
  height:2' coordorigin="6,6" coordsize="9092,2">
  <v:shape id="_x0000_s1052" style='position:absolute;left:6;top:6;width:9092;
   height:2' coordorigin="6,6" coordsize="9092,0" path="m6,6r9091,e" filled="f"
   strokeweight=".58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1041" style='width:455.9pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9118,12">
 <v:group id="_x0000_s1042" style='position:absolute;left:6;top:6;width:9106;
  height:2' coordorigin="6,6" coordsize="9106,2">
  <v:shape id="_x0000_s1043" style='position:absolute;left:6;top:6;width:9106;
   height:2' coordorigin="6,6" coordsize="9106,0" path="m6,6r9105,e" filled="f"
   strokeweight=".20497mm">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="609" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1034" type="#_x0000_t75" style='width:455.9pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Adverse Events in Relation to Dose</strong></p><p>The potential dose dependency of common adverse events (defined as an incidence rate of &ge; 5% in either the 10 mg or 20 mg escitalopram groups) was examined on the basis of the combined incidence of adverse events in two fixed dose trials. The overall incidence rates of adverse events in 10 mg escitalopram treated patients (66%) was similar to that of the placebo treated patients (61%), while the incidence rate in 20 mg/day escitaloram treated patients was greater (86%). Common adverse events that occurred in the 20 mg/day escitalopram group with an incidence approximately twice that of the 10 mg/day escitalopram group and approximately twice that of the placebo group are shown below.<!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1038" style='width:455.15pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9103,12">
 <v:group id="_x0000_s1039" style='position:absolute;left:6;top:6;width:9092;
  height:2' coordorigin="6,6" coordsize="9092,2">
  <v:shape id="_x0000_s1040" style='position:absolute;left:6;top:6;width:9092;
   height:2' coordorigin="6,6" coordsize="9092,0" path="m6,6r9091,e" filled="f"
   strokeweight=".58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="608" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1035" type="#_x0000_t75" style='width:455.15pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Incidence</strong><strong> </strong><strong>of common adverse events* in patients with major depression receiving placebo, 10 mg/day escitalopram, or 20 mg/day escitalopram</strong></p><p><strong>&nbsp;</strong></p><p><strong>ADVERSE</strong><strong> EVENT&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; PLACEBO<strong> </strong>&nbsp; &nbsp; &nbsp; &nbsp; 10 mg/day Escitalopram</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <strong>20 mg/day Escitalopram</strong></p><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp;(n=311)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(n=310)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(n = 125)</strong><img width="608" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1037" type="#_x0000_t75" style='width:455.15pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>Insomnia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14%</p><p>Diarrhoea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14%</p><p>Dry mouth&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9%</p><p>Somnolence&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9%</p><p>Dizziness&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7%</p><p>Sweating increased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1%&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 3%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8%</p><p>Constipation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6%</p><p>Fatigue&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;2%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6%</p><p>Indigestion&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6%<!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1029" style='width:455.15pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9103,12">
 <v:group id="_x0000_s1030" style='position:absolute;left:6;top:6;width:9092;
  height:2' coordorigin="6,6" coordsize="9092,2">
  <v:shape id="_x0000_s1031" style='position:absolute;left:6;top:6;width:9092;
   height:2' coordorigin="6,6" coordsize="9092,0" path="m6,6r9091,e" filled="f"
   strokeweight=".58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="608" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1038" type="#_x0000_t75" style='width:455.15pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>* &nbsp;adverse events with an incidence rate of at least 5% in either escitalopram group and with an incidence rate in 20 mg/day escitalopram group that was approximately twice that of the 10 mg/day escitalopram group and the placebo group.</p><p>&nbsp;</p><p><strong>Vital Sign Changes</strong></p><p>Escitalopram and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with escitalopram treatment.</p><p>&nbsp;</p><p><strong>ECG Changes</strong></p><p>Cases of QT prolongation have been reported during the post-marketing period with both c i t al opr am and es c i t al opr am . C i tal opr am &nbsp;c an &nbsp;c aus e&nbsp; dos e - dependent&nbsp; Q T &nbsp;interval prolongation. In an ECG study, the observed change from baseline QTC (Fridericia correction) was 7.5 msec at the 20mg/day dose and 16.7 msec at the 60mg/day dose of citalopram. The effect of escitalopram on the QT interval was similarly studied at doses of 10mg/day and 30mg/day. The change from baseline QTc (Fridericia correction) was 4.3 msec at the 10mg/day dose and 10.7 msec with the above recommended dose of 30mg/day. The QTc interval prolongation observed with 60mg citalopram exceeded that observed with&nbsp; 30mg escitalopram. It is probable that the R-enantiomer and&nbsp; its metabolites in racemic citalopram contribute to these effects.</p><p>&nbsp;</p><p><strong>Weight Changes</strong></p><p>Patients treated with escitalopram in controlled trials did not differ from placebo-treated patients with regard to clinically important change in body weight.</p><p>&nbsp;</p><p><strong>Laboratory Changes</strong></p><p>In clinical studies, there were no signals of clinically important changes in either various serum chemistry, haematology, and urinalysis parameters associated with escitalopram treatment compared to placebo or in the incidence of patients meeting the criteria for potentially clinically significant changes from baseline in these variables.</p><p>&nbsp;</p><p>For abnormal laboratory changes registered as either <em>uncommon events </em>or <em>serious adverse events from ongoing trials </em>and observed during (but not necessarily caused by) treatment with escitalopram, please refer to &ldquo;Other Events Observed During the Pre-Marketing Evaluation of Escitalopram&rdquo;.</p><p>&nbsp;</p><p><strong>Other Changes Observed During the Pre-Marketing Evaluation of Escitalopram</strong></p><p>Following is a list of WHO terms that reflect adverse events occurring at an incidence of &lt; 1% and serious adverse events from ongoing trials. All reported events are included except those already listed in the table or elsewhere in the <strong>ADVERSE EFFECTS </strong>section, and those occurring in only one patient. It is important to emphasise that, although the events reported occurred during treatment with escitalopram, they were not necessarily caused by it.</p><p>&nbsp;</p><p>Events are further categorised by body system and are listed below. Uncommon adverse events are those occurring in less than 1/100 patients but at least 1/1,000 patients.</p><p>&nbsp;</p><p><u>Application Site Disorders</u></p><p>Uncommon: &nbsp;otitis externa, cellulitis.</p><p>&nbsp;</p><p><u>Body as a W hole</u></p><p>Uncommon: allergy, aggravated allergy, allergic reactions, asthenia, carpal tunnel syndrome, chest pain, chest tightness, fever, hernia, leg pain, limb pain, neck pain, oedema, oedema of extremities, peripheral oedema, rigors, malaise, syncope, scar.</p><p>&nbsp;</p><p><u>Cardiovascular Disorders, General</u></p><p>Uncommon: hypertension aggravated, hypotension, hypertension, abnormal ECG.</p><p>&nbsp;</p><p><u>Central and Peripheral Nervous System Disorders</u></p><p>Uncommon: ataxia, dysaesthesia, disequilibrium, dysgeusia, dystonia, hyperkinesia, hyperreflexia, hypertonia, hypoaesthesia, leg cramps, lightheadedness, muscle contractions, nerve root lesion, neuralgia, neuropathy, paralysis, sedation, tetany, tics, twitching, vertigo.</p><p>&nbsp;</p><p><u>Gastrointestinal System Disorders</u></p><p>Uncommon: abdominal cramp, abdominal discomfort, belching, bloating, change in bowel habit, colitis, colitis ulcerative, enteritis, epigastric discomfort, gastritis, gastroesophageal reflux, haemorrhoids, heartburn, increased stool frequency, irritable bowel syndrome, melaena, periodontal destruction, rectal haemorrhage, tooth disorder, toothache, ulcerative stomatitis.</p><p>&nbsp;</p><p><u>Hearing and Vestibular Disorders</u></p><p>Uncommon: &nbsp;deafness, earache, ear disorder, otosalpingitis, tinnitus.</p><p>&nbsp;</p><p><u>Heart Rate and Rhythm Disorders</u></p><p>Uncommon: &nbsp;bradycardia, tachycardia.</p><p>&nbsp;</p><p><u>Liver and Biliary System Disorders</u></p><p>Uncommon: &nbsp;bilirubinaemia, hepatic enzymes increased.</p><p>&nbsp;</p><p><u>Metabolic and Nutritional Disorders</u></p><p>Uncommon: abnormal glucose tolerance, diabetes mellitus, gout, hypercholesterolaemia, hyperglycaemia, hyperlipaemia, thirst, weight decrease, xerophthalmia.</p><p>&nbsp;</p><p><u>Musculoskeletal System Disorders</u></p><p>Uncommon: arthritis, arthropathy, arthrosis, bursitis, costochondritis, fascitis plantar, fibromyalgia, ischial neuralgia, jaw stiffness, muscle cramp, muscle spasms, muscle stiffness, muscle tightness, muscle weakness, myalgia, myopathy, osteoporosis, pain neck/shoulder, tendinitis, tenosynovitis.</p><p>&nbsp;</p><p><u>Myo-, Endo- and Pericardial and Valve Disorders</u></p><p>Uncommon: myocardial infarction, myocardial ischaemia, myocarditis, angina pectoris.</p><p>&nbsp;</p><p><u>Neoplasm</u></p><p>Uncommon: &nbsp;female breast neoplasm, ovarian cyst, uterine fibroid.</p><p>&nbsp;</p><p><u>Platelet, Bleeding and Clotting Disorders</u></p><p>Uncommon:&nbsp; &nbsp;abnormal &nbsp;bleeding, &nbsp;predominantly &nbsp;of &nbsp;the &nbsp;skin &nbsp;and &nbsp;mucous &nbsp;membranes, &nbsp;including purpura, epistaxis, haematomas, vaginal bleeding and gastrointestinal bleeding.</p><p>&nbsp;</p><p><u>Poison Specific Terms</u></p><p>Uncommon: &nbsp;sting.</p><p>&nbsp;</p><p><u>Psychiatric Disorders</u></p><p>Uncommon: aggressive reaction, amnesia, apathy, bruxism, carbohydrate craving, concentration impairment, confusion, depersonalisation, depression, depression aggravated, emotional lability, excitability, feeling unreal, forgetfulness, hallucination, hypomania, increased appetite, irritability, jitteriness, lethargy, loss of libido, obsessive-compulsive disorder, panic reaction, paroniria, restlessness aggravated, sleep disorder, snoring, suicide attempt, thinking abnormal.</p><p>&nbsp;</p><p><u>Red Blood Cell Disorders</u></p><p>Uncommon: &nbsp;anaemia hypochromic, anaemia.</p><p>&nbsp;</p><p><u>Reproductive Disorders / Female</u></p><p>Uncommon: amenorrhoea, atrophic vaginitis, breast pain, genital infection, intermenstrual bleeding, menopausal symptoms, menorrhagia, menstrual cramps, menstrual disorder, premenstrual tension, postmenopausal bleeding, sexual function abnormality, unintended pregnancy, dysmenorrhoea, vaginal haemorrhage, vaginal candidiasis, vaginitis.</p><p>&nbsp;</p><p><u>Reproductive Disorders / Male</u></p><p>Uncommon: &nbsp;ejaculation delayed, prostatic disorder.</p><p>&nbsp;</p><p><u>Resistance Mechanism Disorders</u></p><p>Uncommon: moniliasis genital, abscess, infection, herpes simplex, herpes zoster, infection bacterial, infection parasitic, infection (tuberculosis), moniliasis.</p><p>&nbsp;</p><p><u>Respiratory System Disorders</u></p><p>Uncommon: asthma, dyspnoea, laryngitis, nasal congestion, nasopharyngitis, pneumonia, respiratory tract infection, shortness of breath, sinus congestion, sinus headache, sleep apnoea, tracheitis, throat tightness.</p><p>&nbsp;</p><p><u>Skin and Appendages Disorders</u></p><p>Uncommon: acne, alopecia, dermatitis, dermatitis fungal, dermatitis lichenoid, dry skin, eczema, erythematous rash, furunculosis, onychomycosis, pruritus, psoriasis aggravated, rash, rash pustular, skin disorder, urticaria, verruca.</p><p>&nbsp;</p><p><u>Secondary Terms</u></p><p>Uncommon: accidental injury, bite, burn, fall, fractured neck of femur, alcohol problem, traumatic haematoma, cyst, food poisoning, lumbar disc lesion, surgical intervention.</p><p>&nbsp;</p><p><u>Special Senses Other, Disorders</u></p><p>Uncommon: dry eyes, eye irritation, taste alteration, taste perversion, visual disturbance, &nbsp;ear infection NOS, vision blurred.</p><p>&nbsp;</p><p><u>Urinary System Disorders</u></p><p>Uncommon: cystitis, dysuria, facial oedema, micturition frequency, micturition disorder, nocturia, polyuria, pyelonephritis, renal calculus, urinary frequency, urinary incontinence, urinary tract infection.</p><p>&nbsp;</p><p><u>Vascular (Extracardiac) Disorders</u></p><p>Uncommon: cerebrovascular disorder, flushing, hot flush [gs], ocular haemorrhage, peripheral ischaemia, varicose vein, vein disorder, vein distended.</p><p>&nbsp;</p><p><u>Vision Disorders</u></p><p>Uncommon: accommodation abnormal, blepharospasm, eye infection, eye pain, mydriasis, vision abnormal, vision blurred, visual disturbance.</p><p>&nbsp;</p><p><u>White Cell and Reticuloendothelial System Disorders</u></p><p>Uncommon: &nbsp;leucopenia.</p><p>&nbsp;</p><p>In addition, the following adverse reactions have been reported with racemic citalopram (all of which have also been reported for other SSRIs):</p><p>&nbsp;</p><p><em>Disorders</em><em> </em><em>of</em><em> </em><em>Metabolism and Nutrition:</em></p><p>Hyponatraemia, inappropriate ADH secretion (both especially in elderly women).</p><p>&nbsp;</p><p><em>Neurological</em><em> </em><em>Disorders:</em></p><p>Convulsions, convulsions grand mal and extrapyramidal disorder, serotonin syndrome (typically characterised by a rapid onset of changes in mental state, with confusion, mania, agitation, hyperactivity, shivering, fever, tremor, ocular movements, myoclonus, hyperreflexia, and inco- ordination).</p><p>&nbsp;</p><p><em>Skin</em><em> </em><em>Disorders:</em></p><p>Ecchymoses, angioedema.</p><p>&nbsp;</p><p>Furthermore, a number of adverse reactions have been listed for other SSRIs. Although these are not listed as adverse reactions for escitalopram or citalopram, it cannot be excluded that these adverse reactions may occur with escitalopram. These SSRI class reactions are listed below:</p><p>&nbsp;</p><p><em>Cardiovascular</em><em> </em><em>Disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>postural hypotension.</p><p><em>Hepatobiliary</em><em> </em><em>Disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>abnormal liver function tests.</p><p><em>Neurological Disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>movement disorders.</p><p><em>Psychiatric</em><em> </em><em>Disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>mania, panic attacks.</p><p><em>Renal and Urinary Disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</em>urinary retention.</p><p><em>Reproductive</em><em> </em><em>Disorders:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>galactorrhoea.</p><p>&nbsp;</p><p><strong>Other Events Observed During the Post-Marketing Evaluation of Escitalopram</strong></p><p>Although no causal relationship to escitalopram treatment has been found, the following adverse events have been reported in association with escitalopram treatment in at least 3 patients (unless otherwise noted) and not described elsewhere in the <strong>ADVERSE EFFECTS </strong>section:</p><p>&nbsp;</p><p>Stomatitis, drug interaction NOS, feeling abnormal, hypersensitivity NOS, non-accidental overdose, injury NOS.</p><p>&nbsp;</p><p>In addition, although no causal relationship to racemic citalopram treatment has been found, the following adverse events have been reported to be temporally associated with racemic citalopram treatment subsequent to the marketing of racemic citalopram and were not observed during the pre-marketing evaluation of escitalopram or citalopram: acute renal failure, akathisia, anaphylaxis, choreoathetosis, delirium, dyskinesia, epidermal necrolysis, erythema multiforme, gastrointestinal haemorrhage, haemolytic anaemia, hepatic necrosis, myoclonus, neuroleptic malignant syndrome, nystagmus, pancreatitis, priapism, prolactinaemia, prothrombin decreased, QT prolonged, rhabdomyolysis, spontaneous abortion, thrombocytopenia, thrombosis, Torsades de&nbsp; pointes, ventricular arrhythmia, and withdrawal syndrome.</p><p>&nbsp;</p><p><strong>Class effect</strong></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In general, the main therapy for all overdoses is supportive and symptomatic use.</p><p>&nbsp;</p><p><strong>Toxicity</strong></p><p>Clinical data on escitalopram overdose are limited and many cases involve concomitant overdoses of other drugs. In the majority of cases, mild or no symptoms have been reported. Doses between 400 and 800 mg of escitalopram alone have been taken without any severe symptoms. No fatalities or sequelae were reported in the few cases with a higher dose (one patient survived ingestion of either 2,400 or 4,800 mg).</p><p>&nbsp;</p><p><strong>Symptoms</strong></p><p>Symptoms seen in reported overdose of escitalopram include symptoms mainly related to the central nervous system (ranging from dizziness, tremor and agitation to rare cases of convulsion and coma), the gastrointestinal system (nausea/vomiting), the cardiovascular system (hypotension, tachycardia, arrhythmia and ECG changes (including QT prolongation)), and electrolyte/fluid balance conditions.</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p>There is no specific antidote. Establish and maintain an airway, ensure adequate oxygenation and respiratory function. The use of activated charcoal should be considered. Activated charcoal may reduce absorption of the drug if given within one or two hours after ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via a nasogastric tube, once the airway is protected. Cardiac and vital signs monitoring are recommended along with general symptomatic supportive measures.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Biochemical and behavioural studies have shown that escitalopram is a potent inhibitor of serotonin (5-HT)-uptake (<em>in vitro </em>IC50 2nM).</p><p>&nbsp;</p><p>The antidepressant action of escitalopram is presumably linked to the potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibitory effect on the reuptake of 5-HT from the synaptic cleft.</p><p>&nbsp;</p><p>Escitalopram is a highly selective Serotonin Reuptake Inhibitor (SSRI). On the basis of <em>in vitro </em>studies, escitalopram had no, or minimal effect on noradrenaline (NA), dopamine (DA) and gamma aminobutyric acid (GABA) uptake.</p><p>&nbsp;</p><p>In contrast to many tricyclic antidepressants and some of the SSRIs, escitalopram has no or very low affinity for a series of receptors including 5-HT1A, 5-HT2, DA D1 and DA D2 receptors, a1-, a2-, &beta;-adrenoceptors, histamine H1, muscarine cholinergic, benzodiazepine, and opioid receptors. A series of functional <em>in vitro </em>tests in isolated organs as well as functional <em>in</em><em> vivo </em>tests have confirmed the lack of receptor affinity.</p><p>&nbsp;</p><p>Escitalopram has high affinity for the primary binding site and an allosteric modulating effect on the serotonin transporter.</p><p>&nbsp;</p><p>Allosteric modulation of the serotonin transporter enhances binding of escitalopram to the primary binding site, resulting in more complete serotonin reuptake inhibition.</p><p>&nbsp;</p><p>Escitalopram is the <em>S</em>-enantiomer of the racemate (citalopram) and is the enantiomer to which the therapeutic activity is attributed. Pharmacological studies have shown that the <em>R</em>-enantiomer is not inert but counteracts the serotonin-enhancing properties of the <em>S-</em>enantiomer in citalopram.</p><p>&nbsp;</p><p>In healthy volunteers and in patients, escitalopram did not cause clinically significant changes in vital signs, ECGs, or laboratory parameters.</p><p>&nbsp;</p><p>S-demethylcitalopram, the main plasma metabolite, attains about 30% of parent compound levels after oral dosing and is about 5-fold less potent at inhibiting 5-HT reuptake than escitalopram <em>in vitro</em>. It is therefore unlikely to contribute significantly to the overall antidepressant effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Data specific to escitalopram are unavailable. Absorption is expected to be almost complete and independent of food intake (mean Tmax is 4 hours after multiple dosing). While the absolute bioavailability of escitalopram has not been studied, it is unlikely to differ significantly from that of racemic citalopram (about 80%).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution (Vd,&beta;/F) after oral administration is about 12 to 26 L/kg. The binding of escitalopram to human plasma proteins is independent of drug plasma levels and averages 55%.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Alternatively, the nitrogen may be oxidised to form the N-oxide metabolite. Both parent and metabolites are partly excreted as glucuronides. Unchanged escitalopram is the predominant compound in plasma. After multiple dosing, the mean concentrations of the demethyl and didemethyl metabolites are usually 28-31% and &lt; 5% of the escitalopram concentration, respectively. Biotransformation of escitalopram to the demethylated metabolite is mediated by a combination of CYP2C19, CYP3A4 and CYP2D6.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination half-life (t&frac12;&beta;) after multiple dosing is about 30 hours and the oral plasma clearance (Cloral) is about 0.6 L/min.</p><p>Escitalopram and major metabolites are, like racemic citalopram, assumed to be eliminated both by the hepatic (metabolic) and renal routes with the major part of the dose excreted as metabolites in urine. Approximately 8.0% of escitalopram is eliminated unchanged in urine and 9.6% as the <em>S</em>-demethylcitalopram metabolite based on 20 mg escitalopram data. Hepatic clearance is mainly by the P450 enzyme system.</p><p>The pharmacokinetics of escitalopram are linear over the clinical dosage range. Steady state plasma levels are achieved in about 1 week. Average steady state concentrations of 50nmol/L (range 20 to 125 nmol/L) are achieved at a daily dose of 10 mg.</p><p>&nbsp;</p><p><u>Reduced Hepatic Function</u></p><p>In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of escitalopram was about twice as long and the exposure was about 60% higher than in subjects with normal liver function (see <strong>PRECAUTIONS </strong>and <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><u>Reduced Renal Function</u></p><p>While there is no specific data, the use of escitalopram in reduced renal function may be extrapolated from that of racemic citalopram. Escitalopram is expected to be eliminated more slowly in patients with mild to moderate reduction of renal function with no major impact on the escitalopram concentrations in serum, At present, no information is available for the treatment of patients with severely reduced renal function (creatinine clearance &lt; 20 mL/min).</p><p>&nbsp;</p><p><u>Elderly Patients (&gt; 65 years)</u></p><p>Escitalopram pharmacokinetics in subjects &gt; 65 years of age were compared to younger subjects in a single-dose and a multiple-dose study. Escitalopram AUC and half-life were increased by approximately 50% in elderly subjects, and Cmax was unchanged. 10 mg is the recommended dose for elderly patients.</p><p>&nbsp;</p><p><u>Gender</u></p><p>In a multiple-dose study of escitalopram (10 mg/day for 3 weeks) in 18 male (9 elderly and 9 young) and 18 female (9 elderly and 9 young) subjects, there were no differences in AUC, Cmax&nbsp;and half-life between the male and female subjects. No adjustment of dosage on the basis of gender is needed.</p><p>&nbsp;</p><p><u>Polymorphism</u></p><p>It has been observed that poor metabolisers with respect to CYP2C19 have twice as high a plasma concentration of escitalopram as extensive metabolisers. No significant change in exposure was observed in poor metabolisers with respect to CYP2D6 (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High doses of escitalopram, which resulted in plasma Cmax&nbsp;for escitalopram and metabolites at least 8-fold greater than anticipated clinically, have been associated with convulsions, ECG abnomalities and cardiovascular changes in experimental animals. Of the cardiovascular changes, cardiotoxicity (including congestive heart failure) was observed in comparative toxicological studies in rats following oral escitalopram or citalopram administration for 4 to 13 weeks and appears to correlate with peak plasma concentrations although its exact mechanism is not clear. Clinical experiences with citalopram, and the clinical trial experience with escitalopram, do not indicate that these findings have a clinical correlation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose, magnesium stearate, croscarmellose sodium, butylated hydroxyanisole, hypromellose, hydroxypropylcellulose, macrogol 8000 and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong> Blister</p><p><strong>Secondary packaging:</strong> Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Pty Ltd
16 Giffnock Avenue Macquarie Park NSW 2113 Australia

Apotex Pty Ltd is the licensee of the registered trade marks AX logo, APO and APOTEX from the registered proprietor, Apotex Inc.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28/12/2011
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>